30 years of preventive studies of uterine cervical cancer 1982–2012

The effectiveness of local destructive treatments (LDT) applied in patients due to cervical pathology oncogenic risk (OR), were followed and verified in 396 patients who came to our attention, focusing on the type of pathology, type of treatment received, diagnosis clinical evolutionary, and results of the new study applying polymerase chain reaction (PCR), and above all, the time between the diagnosis, treatment, and PCR findings. The clinical evolution of the same reports achieved a healing rate of 82% followed by persistence 8.3%; improvement 4.8%, recurrence 2.8%, and only one case of progression 0.2%. The elapsed time in initial care and treatment was almost immediate, as the pathology diagnosis was considered on an emergency basis. Successive controls of these indicated that 119 studies of routine colposcopy were carried out, on an average of the first three years and with a maximum follow up of 30 years, with over 30 routine colposcopies that achieved healing in most of these. In 2011 and 2012, we added to the usual diagnostic methodology, molecular biology, and 119 studies were performed in those patients, resulting in only five negative cases. Most studies were classified as high risk papillomavirus (HR-HPV), corresponding to subtypes 31, 35, 18, and 16.

Oncogenic risk prevention; Cervical cancer: Treatment evolution.

[1] Armstrong E.P.: “Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types". J. Manag. Care Pharm., 16, 217.

[2] World Health Organization: “Fact sheet No. 297: Cancer”. Geneva, updated 2014. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/

[3] “GLOBOCAN 2002 database: summary table by cancer”. Available at: http://globocan.iarc.fr/Default.aspx

[4] Kent A.: “HPV vaccination and testing”. Rev. Obstet. Gynecol., 2010, 3, 33.

[5] “NCCC National Cervical Cancer Coalition”. Available at: http://web.archive.org/web/20080822004150/http://www.nccc-online.org

[6] Lozano R.: “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet, 2012, 380, 2095.

[7] Canavan T.P., Doshi N.R.: “Cervical cancer”. Am. Fam. Physician, 2000, 61, 1369.

[8] Gadducci A., Barsotti C., Cosio S.; Domenici L.; Riccardo Genazzani A.: “Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: A review of the literature”. Gynecol. Endocrinol., 2011, 27, 597. doi:10.3109/09513590.2011.558953

[9] Campbell S., Monga A.: “Gynaecology by Ten Teachers”. 18th ed. London: Hodder Education, 2006.

[10] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[11] Garrido J.L.: “Apporte dela colposcopia di fronte all infezione del HPV puro ed associato alle displasie e cancro”. Congresso LXIX SIGO 1993, 562.

[12] Garrido J.L.: “Screening of cervical cancer: 27 years experience in six Republics of Panama”. Clin. Exp. Obstet. Gynecol., 2012, 39, 343.

[13] Garrido J.L.: “Incidencia patológica de pacientes primerizas al estudio colpo-citológico 1984-1986”. Ginecologia clínica, 1989, 10, 111.

[14] Dexeus S. “CIN Treatments”. Eur. J. Gynaecol. Oncol., 1989, 20, 285.

[15] Machado F.A., Janssens J.P., Michelin M.A., Murta E.F. “Immune response and immunotherapy in intraepithelial and invasive lesions of the uterine cervix”. Clin. Exp. Obstet. Gynecol., 2012, 39, 27.

[16] Michelin M.A., Murta E.F.: “Potential therapeutic vaccine strategic and relevance of the immune system in uterine cervical cancer”. Eur. J. Gynaecol. Oncol., 2008, 29, 10.

[17] Deligeoroglou E., Christopoulos P., Aravantinos L., Papadias K. “Human papilloma virus molecular profile and mechanisms of cancerogenesis: a review”. Eur. J. Gynaecol. Oncol., 2009, 30, 128.

[18] Agnantis N.J., Sotiriadis A., Paraskevaidis E.: “The current status of HPV DNA testing”. Eur. J. Gynaecol. Oncol., 2003, 24, 351. [19] Christopoulos P., Papadias K., Panoulis K., Deligeoroglou E.: “Human papillomavirus in adolescence”. Clin. Exp. Obstet. Gynecol., 2009, 35, 248

[20] Garrido J.L.: “Comparative findings of oncogenic cervical risk and its follow-up in two different periods 1982-1999 and 2000-2010”. Eur. J. Gynaecol. Oncol., 2010, 31, 559.

[21] Tuncer Z.S., Boyraz G., Sahin N., Alp A.: “Distribution of human papillomavirus types in Turkish women”. Eur. J. Gynaecol. Oncol., 2012, 33, 204.

[22] Brinkman J.A., Caffrey A.S., Muderspach L.I., Roman L.D., Kast W.M.: “The impact of anti HPV vaccination on cervical cancer: consequences for clinical management”. Eur. J. Gynaecol. Oncol., 2005, 26, 129.

[23] Szarewski A.: “Prophylactic HPV vaccines”. Eur. Gynaecol. Oncol., 2007, 38, 165.

[24] Syrjanen K.: “Persistent high risk human papillomavirus HPV infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation non 16/18 prophylactic HPV vaccines”. Eur. J. Gynaecol. Oncol., 2011, 32, 17.